Advertisement
Canada markets closed
  • S&P/TSX

    24,822.54
    +132.06 (+0.53%)
     
  • S&P 500

    5,864.67
    +23.20 (+0.40%)
     
  • DOW

    43,275.91
    +36.86 (+0.09%)
     
  • CAD/USD

    0.7246
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    69.34
    -1.33 (-1.88%)
     
  • Bitcoin CAD

    94,368.97
    +251.69 (+0.27%)
     
  • XRP CAD

    0.74
    -0.01 (-1.15%)
     
  • GOLD FUTURES

    2,736.40
    +28.90 (+1.07%)
     
  • RUSSELL 2000

    2,276.09
    -4.76 (-0.21%)
     
  • 10-Yr Bond

    4.0730
    -0.0230 (-0.56%)
     
  • NASDAQ

    18,489.55
    +115.94 (+0.63%)
     
  • VOLATILITY

    18.03
    -1.08 (-5.65%)
     
  • FTSE

    8,358.25
    -26.88 (-0.32%)
     
  • NIKKEI 225

    38,981.75
    +70.56 (+0.18%)
     
  • CAD/EUR

    0.6666
    -0.0024 (-0.36%)
     

Is UnitedHealth Group Incorporated's (NYSE:UNH) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

UnitedHealth Group (NYSE:UNH) has had a great run on the share market with its stock up by a significant 10% over the last month. Since the market usually pay for a company’s long-term fundamentals, we decided to study the company’s key performance indicators to see if they could be influencing the market. In this article, we decided to focus on UnitedHealth Group's ROE.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

View our latest analysis for UnitedHealth Group

How To Calculate Return On Equity?

ROE can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for UnitedHealth Group is:

24% = US$22b ÷ US$94b (Based on the trailing twelve months to September 2023).

The 'return' is the yearly profit. That means that for every $1 worth of shareholders' equity, the company generated $0.24 in profit.

What Has ROE Got To Do With Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

UnitedHealth Group's Earnings Growth And 24% ROE

To begin with, UnitedHealth Group has a pretty high ROE which is interesting. Additionally, the company's ROE is higher compared to the industry average of 11% which is quite remarkable. This probably laid the groundwork for UnitedHealth Group's moderate 11% net income growth seen over the past five years.

Next, on comparing UnitedHealth Group's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 11% over the last few years.

past-earnings-growth
past-earnings-growth

Earnings growth is an important metric to consider when valuing a stock. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is UNH fairly valued? This infographic on the company's intrinsic value has everything you need to know.

Is UnitedHealth Group Making Efficient Use Of Its Profits?

UnitedHealth Group has a healthy combination of a moderate three-year median payout ratio of 30% (or a retention ratio of 70%) and a respectable amount of growth in earnings as we saw above, meaning that the company has been making efficient use of its profits.

Besides, UnitedHealth Group has been paying dividends for at least ten years or more. This shows that the company is committed to sharing profits with its shareholders. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 25%. As a result, UnitedHealth Group's ROE is not expected to change by much either, which we inferred from the analyst estimate of 24% for future ROE.

Conclusion

In total, we are pretty happy with UnitedHealth Group's performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.